Publications
Specialty
Search
EMSWorld
10/28/2024
WyoFile journalist Madelyn Beck's series on Wyoming’s embattled EMS industry unpacks a notoriously underreported field. Learn more about the series from the writer herself.
APP Institute Oncology
10/28/2024
According to second interim data from the MARIPOSA-2 trial, amivantamab plus chemotherapy numerically improved the overall survival, and significantly prolonged the post-progression outcomes among patients with EGFR-mutant non-small cell lung cancer.
APP Institute Oncology
10/28/2024
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment with amivantamab.
APP Institute Oncology
10/28/2024
A novel EGFR x HER3 bispecific ADC showed encouraging antitumor activity for heavily-pretreated advanced urothelial carcinoma.
APP Institute Oncology
10/28/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, EP Lab Digest
10/28/2024
The pivotal investigational device exemption (IDE) study, which enrolled 256 patients at 18 sites in the US, met the primary endpoint. MACCE (Major Adverse Cardiac and Cerebrovascular Events) rate at 30 days was 6.3%, significantly below the pre-defined performance goal (see figure 1).
Vascular Disease Management, CardioVascular, Journal of Invasive Cardiology
10/28/2024
First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase
Podiatry Today, Podiatry
10/28/2024
Podiatry Today spoke to Nicholas R. Butler, DPM, AACFAS, FACPM, FASPS, about his ASPS presentation on the evolution of the Lapidus arthrodesis.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/28/2024
The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoint and revealed significant economic and resource utilization advantages for the non-invasive FFRangio technology over traditional wire-based approaches.
Psych Congress Network
10/28/2024
Christoph Correll, MD, offers clinical guidance for managing adverse affects from schizophrenia treatment, including weight gain and movement disorder
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/28/2024
The Armery solution maximizes support and protection during radial procedures, and furthers Rampart’s mission to provide radiation protection solutions for healthcare teams delivering care in interventional suites.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/27/2024
The A-FLUX Reducer System is engineered with SwiftCell Technology™, a small-cell proprietary design based on computational modeling, to redistribute oxygen supply to the sub-endocardium layer of the heart muscle.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/27/2024
The SirPlux Duo DCB is designed to deliver sirolimus and paclitaxel simultaneously to inhibit cell growth at a higher potency and efficient dose.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/27/2024
The Adona device includes a shunt that features a flow channel with an adjustable geometry that can be made larger or smaller post-implantation via the use of a proprietary induction catheter.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/27/2024
HeartFlow News
Journal of Clinical Pathways
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
Lymphoma, Leukemia & Myeloma Network, Oncology
10/25/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the clinic.
Journal of Clinical Pathways
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
EP Lab Digest
10/25/2024
Medtronic Press Release
GALWAY, Ireland, Oct. 24, 2024 -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one, high-density (HD) mapping and pulsed field (PF) and radiofrequency (RF) ablation catheter for treatment of persistent atrial fibrillation (AFib) and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/25/2024
With this decision, five of the seven Medicare Administrative Contractors (MACs) will soon provide coverage for AI-enabled quantitative coronary plaque analysis, expanding accessibility to over 70 percent of eligible Medicare patients across the United States.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
